Kemudin I.M.

Ceftriaxone, the active ingredient in Kemudin I.M., is a third‑generation cephalosporin presented as an injection for intramuscular use. It treats a range of serious bacterial infections in adults and children as prescribed by a healthcare professional.

GNH USA supplies Kemudin I.M. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat serious bacterial infections.

Community‑acquired pneumonia: eliminates causative bacteria and improves respiratory function. Meningitis: penetrates the cerebrospinal fluid to eradicate the infecting organisms. Gonorrhea: provides rapid bacterial clearance in uncomplicated infections. Urinary tract infections: resolves infection caused by susceptible gram‑negative and gram‑positive pathogens. Skin and soft‑tissue infections: treats cellulitis and related conditions caused by susceptible organisms. Intra‑abdominal infections: targets mixed flora in peritonitis and intra‑abdominal abscesses.

Ceftriaxone may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or erythema. - Diarrhea or loose stools. - Nausea or vomiting. - Rash or mild pruritus. - Elevated liver enzymes. - Transient increase in bilirubin.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Clostridioides difficile‑associated colitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemolytic anemia. - Thrombophlebitis at the injection site. - Severe hepatic dysfunction or jaundice.

Ceftriaxone requires careful consideration of patient‑specific factors and handling conditions.

Renal impairment: adjust dosing as recommended by the prescriber. Hepatic dysfunction: monitor liver function tests during therapy. Allergy to β‑lactams: avoid use in patients with known hypersensitivity. Pregnancy and lactation: use only when the benefit outweighs potential risk. Neonates (≤28 days) and premature infants: avoid intramuscular administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftriaxone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Calcium‑containing IV solutions: may precipitate, avoid co‑administration. - Live bacterial vaccines: reduced efficacy, avoid concurrent use. - Neomycin: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Probenecid: reduces renal clearance, may increase ceftriaxone levels. - Aminoglycosides: additive nephrotoxicity, monitor renal function.